Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of CAT-2054 in Healthy Subjects
NCT02374047Phase 1Completed
- Sponsor
- Astria Therapeutics
- Start
- Jan 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CAT-2054 in hypercholesterolemia (12 cohorts), sponsored by Astria Therapeutics. Primary endpoint: Frequency and severity of adverse events up to 3 weeks. Started Jan 2015; status: completed.
02
Drugs
CAT-2054
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02374047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02374047.